161 related articles for article (PubMed ID: 35648974)
21. Strategies for detecting colon cancer in patients with inflammatory bowel disease.
Bye WA; Nguyen TM; Parker CE; Jairath V; East JE
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD000279. PubMed ID: 28922695
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.
Mantovani A; Zaza G; Byrne CD; Lonardo A; Zoppini G; Bonora E; Targher G
Metabolism; 2018 Feb; 79():64-76. PubMed ID: 29137912
[TBL] [Abstract][Full Text] [Related]
23. Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Wang L; Sang B; Zheng Z
Front Aging Neurosci; 2022; 14():985109. PubMed ID: 36204558
[TBL] [Abstract][Full Text] [Related]
24. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.
Martínez-Domínguez SJ; García-Mateo S; Laredo V; Gargallo-Puyuelo CJ; Gallego Llera B; López de la Cruz J; Gomollón F
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444477
[TBL] [Abstract][Full Text] [Related]
25. Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review.
Spagnuolo R; Abenavoli L; Corea A; Larussa T; Mancina RM; Cosco C; Luzza F; Doldo P
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5818-5825. PubMed ID: 34604973
[TBL] [Abstract][Full Text] [Related]
26. Pregnane X Receptor Polymorphisms and Risk of Inflammatory Bowel Disease: A Meta-Analysis.
Guo X; Yan M
Immunol Invest; 2017 Aug; 46(6):566-576. PubMed ID: 28742404
[TBL] [Abstract][Full Text] [Related]
27. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
Boustany A; Rahhal R; Mitri J; Onwuzo S; Abou Zeid HK; Baffy G; Martel M; Barkun AN; Asaad I
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1067-1074. PubMed ID: 37577829
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
[TBL] [Abstract][Full Text] [Related]
29. Use of histamine-2 receptor antagonists and risk of inflammatory bowel diseases: A systematic review and meta-analysis of observational studies.
D'sa FF; Fernandes EZ; Kesarkar SV; Swaminathan L; Kunhikatta V; Rashid M; Thunga G; Chandran VP; Nair S
J Clin Pharm Ther; 2022 Aug; 47(8):1103-1111. PubMed ID: 35403222
[TBL] [Abstract][Full Text] [Related]
30. The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Pan K; Xu J; Xu Y; Wang C; Yu J
Pharmacol Res; 2024 Jul; 205():107251. PubMed ID: 38862070
[TBL] [Abstract][Full Text] [Related]
31. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Targher G; Byrne CD; Lonardo A; Zoppini G; Barbui C
J Hepatol; 2016 Sep; 65(3):589-600. PubMed ID: 27212244
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
Papaefthymiou A; Potamianos S; Goulas A; Doulberis M; Kountouras J; Polyzos SA
J Crohns Colitis; 2022 Jun; 16(5):852-862. PubMed ID: 34972203
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
[TBL] [Abstract][Full Text] [Related]
34. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease.
Jarmakiewicz-Czaja S; Sokal A; Pardak P; Filip R
Can J Gastroenterol Hepatol; 2022; 2022():4344905. PubMed ID: 35600209
[TBL] [Abstract][Full Text] [Related]
35. Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Aggarwal M; Garg R; Parthasarthy G; Nowacki AS; Padival R; McCullough A; Qazi T; Click B; Rieder F; Cohen BL
Dig Dis Sci; 2023 Mar; 68(3):1006-1015. PubMed ID: 35731428
[TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis.
Xue J; Xin H; Ren N; Zhou C; Yang J; Song L; Qin S
Eur J Clin Invest; 2019 Sep; 49(9):e13158. PubMed ID: 31338830
[TBL] [Abstract][Full Text] [Related]
37. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis.
Chen M; Yuan C; Xu T
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):302-309. PubMed ID: 31447293
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis.
Ciardullo S; Grassi G; Mancia G; Perseghin G
Eur J Gastroenterol Hepatol; 2022 Apr; 34(4):365-371. PubMed ID: 34678858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
